Source: Pharmacy Times articles
The FDA grants fast track designation to TEV-53408, a promising treatment for celiac disease designed to address gluten intolerance and improve patient outcomes.
Read More
by MM360 Staff | May 30, 2025 | Myeloma News | 0 comments
Source: Pharmacy Times articles
The FDA grants fast track designation to TEV-53408, a promising treatment for celiac disease designed to address gluten intolerance and improve patient outcomes.
Read More